Wegovy® through Hims
Wegovy® can help you lose up to 20% of your body weight—and keep it off—when combined with diet and exercise.*
Important Safety Information
Partner with clinicians to customise your treatment plan
If eligible, your treatment will be delivered directly to your door and you will have access to dynamic tools through the Care Portal
Access to unlimited messaging and ongoing check-ins with licensed clinicians
Guidance on sleep, nutrition, exercise and more via your Care Portal
Actual price will depend on subscription plan purchase. Requires an online consultation with a healthcare provider who will determine if treatment is appropriate. *Based on two separate Wegovy® clinical studies. In a 68-week study, about 1 in 3 adults with obesity or overweight and weight-related conditions achieved 20% weight loss. Average weight loss achieved was 15%. In a 104-week study, mean weight loss achieved at 2 years was 15.2% vs. 2.6% for placebo. Individual results may vary. Stopping treatment may result in weight regain. Wegovy® is a registered trade mark of Novo Nordisk A/S. Hims & Hers Health, Inc. is not affiliated with or endorsed by Novo Nordisk A/S.
Lose up to 20%
of your body weight* and improve your overall health with Wegovy®**through Hims
Along with a reduced calorie diet and increased exercise. In a 104-week clinical study of Wegovy® in adults with obesity or overweight and weight-related medical problems, mean weight loss achieved at 2 years was 15.2% vs. 2.6% for placebo. Individual results may vary. Stopping treatment may result in weight regain. *Based on a Wegovy® study, where about 1 in 3 adults with obesity or overweight and weight-related conditions achieved 20% weight loss. Average weight loss achieved was 15%. Individual results may vary. **Based on two sets of individual clinical studies in adults with obesity or overweight, where those with diabetes were excluded. Wegovy® is not indicated to treat hypertension, type 2 diabetes, or dyslipidemia. In a 2-year study, Wegovy® was associated with improvements in blood pressure, cholesterol, and A1c. In a separate study of people with heart disease, Wegovy® reduced the risk of major cardiovascular events by 20%.
More than medication
Access Wegovy® through Hims with a comprehensive plan designed for long term weight management
*Along with a reduced calorie diet and increased exercise. In a 104-week clinical study of Wegovy® in adults with obesity or overweight and weight-related medical problems, mean weight loss achieved at 2 years was 15.2% vs. 2.6% for placebo. Individual results may vary. Stopping treatment may result in weight regain.
Simulated interaction